{"id":"W4310798566","doi":"10.1016/j.esmoop.2022.100634","title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Hospital Foundation","funders":"Ministero della Salute; Amgen; Prostate Cancer Foundation","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Internal medicine; Overall survival; Oncology; Progression-free survival; Expanded access; Response Evaluation Criteria in Solid Tumors; Urology; Cancer; Progressive disease; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002006674,0.0003484526,0.0003484464,0.0007579796,0.0002347311,0.0005868,0.0004120028,0.0003291621,0.0007149476],"category_scores_gemma":[0.004284931,0.0001280444,0.000431475,0.000687592,0.0003006086,0.0002817535,0.0008403959,0.0003572001,0.0002096591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004330144,"about_ca_system_score_gemma":0.0004947617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001883143,"about_ca_topic_score_gemma":0.002661753,"domain_scores_codex":[0.9989331,0.0004687871,0.0000711742,0.0001518037,0.0002410497,0.0001340551],"domain_scores_gemma":[0.9979881,0.0005290194,0.0007920159,0.0001533765,0.0002221841,0.000315297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004510255,0.00003227349,0.9968165,0.000006851831,0.00002855834,0.00004588922,0.00002824027,0.0001877917,0.0001575637,0.00001219759,0.0001050005,0.002128064],"study_design_scores_gemma":[0.00002301943,0.0003686901,0.9979202,0.000004056667,0.00002276879,0.000259644,0.00004019783,0.0009486729,0.0001700056,0.00001927415,0.0002212279,0.000002202049],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9993435,0.00004926947,0.0001021276,0.0000209718,0.000002477503,0.00001327938,0.0001737184,0.000002902484,0.0002918172],"genre_scores_gemma":[0.9993518,0.00001542506,0.0001191293,0.000008673805,0.000006471763,0.00001151715,0.0004336802,0.000001235764,0.00005223218],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002006674,"threshold_uncertainty_score":0.01061249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0410528661734179,"score_gpt":0.2901908751238391,"score_spread":0.2491380089504212,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}